Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 24.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,283 shares of the biopharmaceutical company’s stock after acquiring an additional 4,967 shares during the period. SG Americas Securities LLC’s holdings in Celldex Therapeutics were worth $639,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics during the second quarter worth $76,000. AQR Capital Management LLC grew its stake in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 1,504 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Celldex Therapeutics by 23.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 2,600 shares during the period. Finally, Point72 DIFC Ltd lifted its stake in Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 7,116 shares in the last quarter.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This trade represents a 39.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Celldex Therapeutics Stock Down 1.0 %

Shares of Celldex Therapeutics stock opened at $25.26 on Friday. Celldex Therapeutics, Inc. has a 52-week low of $22.17 and a 52-week high of $53.18. The company has a 50 day moving average of $25.63 and a 200 day moving average of $31.17. The company has a market capitalization of $1.68 billion, a P/E ratio of -9.83 and a beta of 1.62.

Analyst Ratings Changes

Several equities analysts have weighed in on CLDX shares. Citigroup started coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.